Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Research
  • Published:

Evaluation of sexual activity in patients treated with tadalafil: a randomized prospective placebo-controlled trial

International Journal of Impotence Research volume 17, pages 76–79 (2005)Cite this article

Abstract

The chronological distribution of sexual intercourses in a group of patients treated with tadalafil versus placebo for 3 months was evaluated. In total, 120 patients with ED were randomized in two groups and treated, respectively, with one pill of tadalafil 20 mg or placebo on Tuesday and on Friday. After 3 months, we collected data using IIEF and SEP diaries. After 3 months, IIEF score and percentages of success SEP diaries increased in the tadalafil group (<0.01) versus placebo group. Considering all the successful intercourses of the 3 months of tadalafil assumption, the highest percentages were reported within 6–12 h range (35%) and 12–24 h range (28%). In tadalafil group, 41% of patients reported their first successful intercourse between 1 and 6 h and 78% of patients reported the recovery of spontaneous erections. In conclusion, after carrying out the first sexual attempt between 1 and 6 h, patients engaged in sexual activity between 6 and 24 h.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. McKinlay JB . The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res 2000; 12: S6.

    Article  Google Scholar 

  2. Carvajal JA, Germain AM, Huidobro-Toro JP, Weiner CP . Molecular mechanism of cGMP mediated smooth muscle relaxation. J Cell Physiol 2000; 184: 409.

    Article  CAS  Google Scholar 

  3. Porst H . IC351 (tadalafil, Cialis). Update on clinical experience. Int J Impot Res 2002; 14(Suppl 1): S57–S64.

    Article  Google Scholar 

  4. Padma-Nathan H, McMurray JG, Pullman WE . On demand IC351 (Cialis™) enhances erectile function in patients with erectile dysfunction. Int J Impot Res 2001; 13: 2–9.

    Article  CAS  Google Scholar 

  5. Padma-Nathan H, Giuliano F . Oral drug therapy for erectile dysfunction. Urol Clin N Am 2001; 28: 321–334.

    Article  CAS  Google Scholar 

  6. Angulo I . IC351 enhances NO-mediated relaxation of human arterial and trabecular penile smooth muscle. Eur Urol 2001; 39(Suppl 5): 106,, (abstract 415).

    Google Scholar 

  7. Giuliano F, Varanese L . Tadalafil: a novel treatment for erectile dysfunction. Eur Heart J 2002; 4(Suppl H): H24–H31.

    Article  CAS  Google Scholar 

  8. Brock G, Iglesias J, Toulouse K . Efficacy and safety of IC351 treatment for ED. Eur Urol 2001; 39(Suppl 5): 106, (abstract).

    Google Scholar 

  9. Brock G et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168: 1332–1336.

    Article  CAS  Google Scholar 

  10. Padma-Nathan H et al. Tadalafil (IC351) provides prompt and extended period of response for the treatment of men with ED. Int J Impot Res 2001; 13(Suppl 5): S64.

    Google Scholar 

  11. Rosen R et al. The International Index of Erectile Function (IIEF): a multidimensional scale fir assessment of erectile dysfunction. Urology 1997; 49: 822–830.

    Article  CAS  Google Scholar 

  12. Cappelleri JC et al. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999; 54: 346.

    Article  CAS  Google Scholar 

  13. Hanson-Divers C et al. Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol 1998; 159: 1541.

    Article  CAS  Google Scholar 

  14. Patterson B et al. Dose-normalized pharmacokinetics of single dose tadalafil (IC351) in healthy volunteers. Int J Impot Res 2001; 13(Suppl 5): S63.

    Google Scholar 

  15. Patterson B et al. The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil (IC351). Int J Impot Res 2001; 13(Suppl 5): S62.

    Google Scholar 

  16. Porst H et al. Tadalafil allows men with erectile dysfunction to have successful intercourse up to 36 h postdose. J Urol 2002; 167(Suppl): 177.

    Google Scholar 

  17. Jannini E, Lenzi A, Wagner G . New perspectives in the pharmacotherapy of erectile dysfunction. Drugs 2003; 6: 1165–1172.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, S Martino's Hospital, University of Genoa, Genoa, Italy

    A F De Rose, F Gallo & G Carmignani

Authors
  1. A F De Rose
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F Gallo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Carmignani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A F De Rose.

Rights and permissions

Reprints and permissions

About this article

Cite this article

De Rose, A., Gallo, F. & Carmignani, G. Evaluation of sexual activity in patients treated with tadalafil: a randomized prospective placebo-controlled trial. Int J Impot Res 17, 76–79 (2005). https://doi.org/10.1038/sj.ijir.3901265

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901265

Keywords

This article is cited by

Search

Advanced search

Quick links